Webb-Walsh Brian J.
Known title: EVP & CFOCIK: 0001688789
Webb-Walsh Brian J.'s purchase track record
Webb-Walsh Brian J. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/8/2024 | VYX | $115K | +23.5% | +14.1% | +14.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VYX | ▼ Sell | Tax Withholding | 58,011 | $480K | 8/1/2026 | View on chart |
| VYX | ▲ Buy | Option Exercise | 27,012 | $0 | 3/15/2026 | View on chart |
| VYX | ▼ Sell | Tax Withholding | 12,674 | $82K | 3/15/2026 | View on chart |
| VYX | ▲ Buy | Option Exercise | 32,082 | $0 | 3/3/2026 | View on chart |
| VYX | ▼ Sell | Tax Withholding | 14,948 | $120K | 3/3/2026 | View on chart |
| VYX | ▲ Buy | Option Exercise | 27,012 | $0 | 3/15/2025 | View on chart |
| VYX | ▼ Sell | Tax Withholding | 12,086 | $117K | 3/15/2025 | View on chart |
| VYX | ▲ Buy | Open Market | 10,000 | $115K | 8/8/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Goldman Sachs cuts NCR Voyix price target to $8
Goldman Sachs maintained a Neutral rating on NCR Voyix but lowered its price target to $8. This action follows the company's recent Q2 2026 earnings call. The new target is below the current average analyst estimate of $12.96, reflecting a cautious outlook from the firm.
Goldman Sachs cuts NCR Voyix price target to $8. Goldman Sachs maintained a Neutral rating on NCR Voyix but lowered its price target to $8. This action follows the company's recent Q2 2026 earnings call. The new target is below the current average analyst estimate of $12.96, reflecting a cautious outlook from the firm.